Trial Profile

Phase I/II clinical trial to evaluate the efficacy and safety of DFP-17729 in patients with unresectable/recurrent/progressive pancreatic cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DFP-17729 (Primary) ; Gimeracil/oteracil/tegafur
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Delta-Fly Pharma

Most Recent Events

04 Dec 2024 According to a Delta Fly Pharma media release, the results from this study were presented at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation.
11 Oct 2022 Status changed from active, no longer recruiting to completed.
25 Nov 2021 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com